Nexvena

My startup, Nexvena, is actively seeking a versatile co-founder brightened by entrepreneurial zeal and shares in our vision to revolutionize extracorporeal life support. We're developing a bidirectional cannula that aims to prevent limb ischemia - a common but severe and costly complication during ECLS and ECMO procedures. Our mission calls for innovating cannulation methods to maximize patient safety and quality of life. Earning an impressive ~$180 million in potential revenue by capturing just 1% of the $18 billion arterial femoral cannula market, potential for growth in our startup is significant. Our team, made up of experts with a significant track record in vascular surgery, software development, and strategic planning, is positioned to face the competition head-on. However, we are missing a strategic co-founder who can complement our strengths and address our weaknesses. Our ideal co-founder will be experienced in the med-tech field with a focus on product development, FDA regulatory pathways, and clinical trials

Nexvena aims to redefine extracorporeal life support by developing a bidirectional cannula that curbs limb ischemia, a common side effect due to restricted blood flow. Despite critical care advancements, current devices fail to protect the limb. Our innovative cannula assures full systemic support while preserving distal perfusion. In essence, it's one device promoting whole body support and limb protection.

Our product addresses limb ischemia during femoral cannulation in ECLS or ECMO. Currently, standard single-lumen femoral cannulas block blood flow to the lower limb, resulting often in serious and preventable complications.